{"organizations": [], "uuid": "ebbf85a87289e087fc95a914ac50a35fa193bcdd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-atara-biotherapeutics-gets-fda-cle/brief-atara-biotherapeutics-gets-fda-clearance-to-proceed-with-multiple-sclerosis-study-idUSFWN1P50CE", "country": "US", "domain_rank": 408, "title": "BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.956, "site_type": "news", "published": "2018-01-10T21:09:00.000+02:00", "replies_count": 0, "uuid": "ebbf85a87289e087fc95a914ac50a35fa193bcdd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-atara-biotherapeutics-gets-fda-cle/brief-atara-biotherapeutics-gets-fda-clearance-to-proceed-with-multiple-sclerosis-study-idUSFWN1P50CE", "ord_in_thread": 0, "title": "BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "atara", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "atara biotherapeutics inc", "sentiment": "negative"}, {"name": "atara biotherapeutics", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - Atara Biotherapeutics Inc:\n* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS\n* ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019 ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T21:09:00.000+02:00", "crawled": "2018-01-11T12:44:36.012+02:00", "highlightTitle": ""}